Faruk Ramadani

Faruk Ramadani

Auto-generated profile, based on publicly available information

Faruk Ramadani

Randall Centre For Cell & Molecular Biophysics, King's College London

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2009 in Science
Verified
Journal Article
Closed access
PDF file
CSColin Selman
Colin Selman
JTJennifer M A Tullet
Jennifer M A Tullet
DWDaniela Wieser
Daniela Wieser
EIElaine Irvine
Elaine Irvine
SLSteven J. Lingard
Steven J. Lingard
DWDominic J. Withers
Dominic J. Withers
Mimicking Caloric Restriction: The extended life span and resistance to age-related diseases in animals exposed to caloric restriction has focused attention on the biochemical mechanisms that produce these effects. Selman et al. (p. 140 ; see the Perspective by Kaeberlein and Kapahi ) explored the role of the mammalian ribosomal protein S6 kinase 1 (S6K1), which regulates protein translation and cellular energy metabolism. Female knockout mice lacking expression of S6K1 showed characteristics of animals exposed to caloric restriction, including improved health and increased longevity. The beneficial effects included reduced fat mass in spite of increased food intake. Thus, inhibition of signaling pathways activated by S6K1 might prove beneficial in protecting against age-related disease.

10 October 2007 in The FASEB Journal
Verified
Journal Article
Closed access
CSColin Selman
Colin Selman
SLSteven Lingard
Steven Lingard
ACAgharul I. Choudhury
Agharul I. Choudhury
RBRachel L. Batterham
Rachel L. Batterham
MCMarc Claret
Marc Claret
DWDominic J. Withers
Dominic J. Withers

17 June 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JGJulie Guillermet-Guibert
Julie Guillermet-Guibert
KBKatja Bjorklof
Katja Bjorklof
ASAshreena Salpekar
Ashreena Salpekar
CGCristiano Gonella
Cristiano Gonella
FRFaruk Ramadani
Faruk Ramadani
BVBart Vanhaesebroeck
Bart Vanhaesebroeck
The p110 isoforms of phosphoinositide 3-kinase (PI3K) are acutely regulated by extracellular stimuli. The class IA PI3K catalytic subunits (p110α, p110β, and p110δ) occur in complex with a Src homology 2 (SH2) domain-containing p85 regulatory subunit, which has been shown to link p110α and p110δ to Tyr kinase signaling pathways. The p84/p101 regulatory subunits of the p110γ class IB PI3K lack SH2 domains and instead couple p110γ to G protein-coupled receptors (GPCRs). Here, we show, using small-molecule inhibitors with selectivity for p110β and cells derived from a p110β-deficient mouse line, that p110β is not a major effector of Tyr kinase signaling but couples to GPCRs. In macrophages, both p110β and p110γ contributed to Akt activation induced by the GPCR agonist complement 5a, but not by the Tyr kinase ligand colony-stimulating factor-1. In fibroblasts, which express p110β but not p110γ, p110β mediated Akt activation by the GPCR ligands stromal cell-derived factor, sphingosine-1-phosphate, and lysophosphatidic acid but not by the Tyr kinase ligands PDGF, insulin, and insulin-like growth factor 1. Introduction of p110γ in these cells reduced the contribution of p110β to GPCR signaling. Taken together, these data show that p110β and p110γ can couple redundantly to the same GPCR agonists. p110β, which shows a much broader tissue distribution than the leukocyte-restricted p110γ, could thus provide a conduit for GPCR-linked PI3K signaling in the many cell types where p110γ expression is low or absent.

10 August 2010 in Science Signaling
Verified
Journal Article
Closed access
PDF file
FRFaruk Ramadani
Faruk Ramadani
DBDaniel J. Bolland
Daniel J. Bolland
FGFabien Garcon
Fabien Garcon
JEJuliet L. Emery
Juliet L. Emery
BVBart Vanhaesebroeck
Bart Vanhaesebroeck
KOKlaus Okkenhaug
Klaus Okkenhaug
Different isoforms of phosphatidylinositol 3-kinase have distinct roles in B cell receptor signaling.

1 March 2012 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MDMelissa Dullaers
Melissa Dullaers
RBRuth De Bruyne
Ruth De Bruyne
FRFaruk Ramadani
Faruk Ramadani
HGHannah J. Gould
Hannah J. Gould
PGPhilippe Gevaert
Philippe Gevaert
BLBart N. Lambrecht
Bart N. Lambrecht

12 April 2011 in Science Signaling
Verified
Journal Article
Closed access
PDF file
SKSuhasini Kulkarni
Suhasini Kulkarni
Cassian SitaruCassian Sitaru
Cassian Sitaru
Zoltan JakusZoltan Jakus
Zoltan Jakus
KAKaren E. Anderson
Karen E. Anderson
GDGeorge Damoulakis
George Damoulakis
PHPhillip T. Hawkins
Phillip T. Hawkins
Neutrophils are activated by immunoglobulin G (IgG)–containing immune complexes through receptors that recognize the Fc portion of IgG (FcγRs). Here, we used genetic and pharmacological approaches to define a selective role for the β isoform of phosphoinositide 3-kinase (PI3Kβ) in FcγR-dependent activation of mouse neutrophils by immune complexes of IgG and antigen immobilized on a plate surface. At low concentrations of immune complexes, loss of PI3Kβ alone substantially inhibited the production of reactive oxygen species (ROS) by neutrophils, whereas at higher doses, similar suppression of ROS production was achieved only by targeting both PI3Kβ and PI3Kδ, suggesting that this pathway displays stimulus strength–dependent redundancy. Activation of PI3Kβ by immune complexes involved cooperation between FcγRs and BLT1, the receptor for the endogenous proinflammatory lipid leukotriene B4. Coincident activation by a tyrosine kinase–coupled receptor (FcγR) and a heterotrimeric guanine nucleotide–binding protein (G protein)–coupled receptor (BLT1) may provide a rationale for the preferential activation of the β isoform of PI3K. PI3Kβ-deficient mice were highly protected in an FcγR-dependent model of autoantibody-induced skin blistering and were partially protected in an FcγR-dependent model of inflammatory arthritis, whereas combined deficiency of PI3Kβ and PI3Kδ resulted in near-complete protection in the latter case. These results define PI3Kβ as a potential therapeutic target in inflammatory disease.